Q1 2026 Net Loss Narrows to $1.53M; Executive Chairman Secures New Compensation Package
QCLS sits 84% above its 52-week low of $2.5.
Summary
Q/C Technologies reported a narrowed net loss and improved EPS for Q1 2026, with management confirming a 12-month liquidity runway, while also disclosing a new compensation package for its Executive Chairman.
Key Events · Earnings and Guidance · QCLS
-
Q1 2026 Financial Performance Improves
The company reported a net loss attributable to common stockholders of $(1.53) million, a significant improvement from $(1.94) million in Q1 2025. Basic and diluted net loss per common share also improved to $(0.19) from $(0.36) year-over-year.
-
Liquidity Position and Cash Runway
As of March 31, 2026, cash and cash equivalents totaled $1.13 million, with marketable securities at $11.85 million. Despite cash used in operating activities increasing to $3.29 million for the quarter, management believes current financial resources are sufficient to fund operations for the next twelve months.
-
Executive Chairman's New Employment Agreement
Effective April 13, 2026, Executive Chairman Joshua Silverman entered a new three-year employment agreement, including an annual base salary of $120,000 and quarterly grants of fully vested restricted stock units (RSUs) valued at $60,000 per grant, plus an additional cash payment for estimated personal income and employment taxes on the RSUs.
-
Strategic Business Pivot Continues
The company reiterated its ongoing strategic shift from pharmaceuticals to energy-efficient blockchain and quantum-class laser-based computing, leveraging an exclusive global licensing agreement with LightSolver Ltd. The legacy pharmaceutical assets are being evaluated for potential divestiture.
Analysis · QCLS · Life Sciences
Q/C Technologies reported a narrower net loss for Q1 2026, improving to $(1.53) million from $(1.94) million year-over-year, and management affirmed sufficient liquidity for the next 12 months. This is critical for a micro-cap company that remains pre-revenue and is undergoing a strategic pivot. Additionally, the Executive Chairman, Joshua Silverman, entered a new employment agreement with a notable compensation package, including significant RSU grants and associated tax payments, which provides transparency into executive incentives.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QCLS was trading at $4.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34M. The 52-week trading range was $2.50 to $33.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.